<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03863860</url>
  </required_header>
  <id_info>
    <org_study_id>FZPL-Ⅲ-301-OC</org_study_id>
    <nct_id>NCT03863860</nct_id>
  </id_info>
  <brief_title>A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients</brief_title>
  <official_title>A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With Fluzoparib Capsules Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy, safety tolerability of maintenance therapy with Fluzoparib(A PARP
      inhibitor) versus placebo in Chinese patients with recurrent ovarian cancer who achieved a
      complete response (CR) or partial response (PR) after platinum-based chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival(PFS) by Blinded Independent Review Committee (BIRC) in relapsed ovarian cancer patients</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Defined as progression free survival per RECIST 1.1 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival(PFS) by BIRC in relapsed ovarian cancer patients with Breast cancer susceptibility gene(BRCA) mutant</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Defined as progression free survival per RECIST 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS) in relapsed ovarian cancer patients</measure>
    <time_frame>up to 2 years</time_frame>
    <description>PFS is Progression-Free-Survival per RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression(TTP) by Gynecological Cancer Intergroup(GCIG) CA 125 criteria</measure>
    <time_frame>up to 2 years</time_frame>
    <description>TTP is Time to Progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy free interval (CFI) CFI</measure>
    <time_frame>up to 2 years</time_frame>
    <description>CFI is the time from last platinum dose until initiation of next anticancer therapy (excluding maintenance therapy if used following the penultimate regimen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival(OS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>OS is the time interval from the start of treatment to death due to any reason or lost of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>At baseline,at the time point of every 12 weeks, up to 2 years</time_frame>
    <description>Objective Response Rate complete or partial response per RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events(AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>from the first drug administration to within 30 days for the last treatment dose</time_frame>
    <description>assess the safety and tolerability of Fluzoparib maintenance monotherapy in platinum sensitive relapsed ovarian cancer patients by record the number of Participants with of AEs and SAEs, and the proportion of patients with AEs and SAEs, etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Fluzoparib capsules, 50mg per capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluzoparib capsules, PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules, 50mg per capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules, PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib capsules</intervention_name>
    <description>Fluzoparib capsules</description>
    <arm_group_label>Fluzoparib capsules, 50mg per capsule</arm_group_label>
    <other_name>SHR-3162</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo capsules, 50mg per capsule</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically diagnosed high-grade serous or endometrioid ovarian cancer (including
             primary peritoneal and fallopian tube cancer)

          2. Completion of ≥2 previous platinum-containing regimens

          3. Complete response (CR) or partial response (PR) achieved with last platinum-based
             chemotherapy regimen as determined by investigator

          4. Ability to be randomized ≤8 weeks after last dose of platinum

        Exclusion Criteria:

          1. Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor

          2. Patients who have received other study drug treatment within 4 weeks prior to the
             first administration(&lt; 5 elimination half-lives of the study drug molecular targeted
             anti-cancer drugs).

          3. Patients with clinical symptoms of cancer ascites, pleural effusion, who need to
             drainage, or who have undergone ascites drainage within 2 months prior to the first
             administration.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lingying Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

